Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Gastrointestinal tumours, non-colorectal

1438 - Low-dose aspirin and risk of gastric and oesophageal cancer: a population-based study


28 Sep 2019


Poster Discussion – Gastrointestinal tumours, non-colorectal


Luis Garcia Rodriguez


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


L. Garcia Rodriguez1, P. Vora2, M. Soriano-Gabarró2, L. Cea Soriano1

Author affiliations

  • 1 Epidemiology, Spanish Centre for Pharmacoepidemiologic Research, 28004 - Madrid/ES
  • 2 Epidemiology, Bayer AG, 13352 - Berlin/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1438


Evidence suggests that low-dose aspirin is associated with a 30–40% protective effect against colorectal cancer (CRC) yet its effect on other gastrointestinal cancers has been less studied. We aimed to quantify the association between use of low-dose aspirin and risk of gastric/ oesophageal cancer using a population-based primary care database in the United Kingdom – The Health Improvement Network.


Among persons aged 40–89 years from 2005–2015, ∼200,000 new users of low-dose aspirin (75–300 mg/day) were each matched to a non-user by age, sex, time since study entry and number of primary care visits in the previous year. Individuals were followed (max. 18 years) to identify incident cases of gastric/oesophageal cancer. Nested case–control analyses were conducted using 5000 controls for both sets of cancer cases frequency matched by age, sex and calendar year. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for current vs. non-use of low-dose aspirin using logistic regression. Current use was when low-dose aspirin use lasted to 0–90 days before the index date (event date for cases, random date for controls) and total duration of use before the index date was >1 year; non-use was no use of low-dose aspirin ever before the index date or use that ended ≥1 year before the index date.


We identified 727 incident cases of gastric cancer and 1394 incident cases of oesophageal cancer. As shown in the table, compared with non-use, current use of low-dose aspirin was associated with a significant 54% reduced risk of gastric cancer and a significant 41% reduced risk of oesophageal cancer. Protective effects were seen for both cancers irrespective of total previous duration of low-dose aspirin use.Table:

681PD Odds ratios (95% confidence intervals) for the association between use of low-dose aspirin (current vs non-use) and gastric/oesophageal cancer

Gastric cancerOesophageal cancer
Cases N = 727 n (%)Controls N = 5000 n (%)Adjusted OR* (95% CI)Cases N = 1394 n (%)Controls N = 5000 n (%)Adjusted OR* (95% CI)
Non-use of low-dose aspirin442 (60.8)2404 (48.1)1.0 (reference)829 (59.5)2555 (51.1)1.0 (reference)
Current use of low-dose aspirin (with duration >1 year)146 (20.1)1407 (28.1)0.46 (0.38-0.57)331 (23.7)1397 (27.9)0.59 (0.51-0.69)
Duration >1 to < 3 years56 (7.7)693 (13.9)0.34 (0.25-0.46)145 (10.4)680 (13.6)0.51 (0.41-0.62)
Duration > =3 years90 (12.4)714 (14.3)0.60 (0.47-0.77)186 (13.3)717 (14.3)0.68 (0.56-0.82)
Remaining current users of low-dose aspirin (i.e. patients with duration <1 year)66 (9.1)730 (14.6)0.31 (0.23-0.42)103 (7.4)625 (12.5)0.33 (0.26-0.42)
Past use of low-dose aspirin (use that ended >90 days before the index date)73 (10.0)459 (9.2)0.61 (0.46-0.80)131 (9.4)423 (8.5)0.65 (0.52-0.81)
Duration <1 year34 (4.7)283 (5.7)0.42 (0.29-0.62)65 (4.7)268 (5.4)0.49 (0.37-0.67)
Duration > =1 year39 (5.4)176 (3.5)0.92 (0.64-1.34)66 (4.7)155 (3.1)0.92 (0.67-1.26)

Adjusted by age, sex and primary care practitioner visits in the year before the index date.


Our results indicate that use of low-dose aspirin is associated with a significantly reduced risk of gastric and oesophageal cancer as supported by mechanistic data.

Clinical trial identification

Editorial acknowledgement

Susan Bromley, EpiMed Communications Ltd (Oxford, UK).

Legal entity responsible for the study

Luis A Garcia Rodriguez.


Bayer AG.


L. Garcia Rodriguez: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Bayer AG. P. Vora: Full / Part-time employment: Bayer AG. M. Soriano-Gabarró: Full / Part-time employment: Bayer AG. L. Cea Soriano: Research grant / Funding (institution): Bayer AG.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.